Sinopharm Group Zhongnuo Pharmaceutical (Shijiazhuang) Co., L

Primary objective: To evaluate the effectiveness of aprepitant injection in preventing postoperative nausea and vomiting (PONV); Secondary objective: To evaluate the safety of aprepitant injection in preventing postoperative nausea and vomiting (PONV);

Primary objective: Using budesonide enteric-coated capsules provided by Shijiazhuang Zhongnuo Pharmaceutical Co., Ltd. as the test preparation and budesonide enteric-coated capsules (trade name: NEFECON) produced by Patheon Pharmaceuticals Inc as the reference preparation, the bioequivalence of the test preparation and the reference preparation in healthy subjects under fasting and postprandial conditions was evaluated according to the relevant provisions of bioequivalence studies. Secondary objective: To observe the safety of healthy subjects after taking the test preparation budesonide enteric-coated capsules or the reference preparation budesonide enteric-coated capsules (trade name: NEFECON).

The primary objective was to use Lansoprazole Enteric-coated Capsules produced by Shijiazhuang Pharmaceutical Group Zhongnuo Pharmaceutical Co., Ltd. as the test preparation and Lansoprazole Enteric-coated Capsules (trade name: Dakopron®) produced by Tianjin Takeda Pharmaceutical Co., Ltd. as the reference preparation. According to the relevant provisions of the bioequivalence test, the pharmacokinetic behavior of Lansoprazole Enteric-coated Capsules in healthy subjects was compared to evaluate the bioequivalence of the two preparations. The secondary objective was to evaluate the safety of the test preparation and the reference preparation of Lansoprazole Enteric-coated Capsules after a single oral administration on an empty stomach or after a meal in healthy subjects.